Randomized Phase 2 Trial Investigating Liposomal Doxorubicin With or Without Anti-Platelet Derived Growth Factor Receptor-Alpha (PDGFRalpha) Monoclonal Antibody IMC-3G3 in Patients With Platinum-Refractory or Platinum-Resistant Advanced Ovarian Cancer.
Phase of Trial: Phase II
Latest Information Update: 19 Apr 2017
At a glance
- Drugs Olaratumab (Primary) ; Doxorubicin liposomal
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly
- 10 Jun 2017 Biomarkers information updated
- 13 Mar 2014 Status changed from active, no longer recruiting to completed.
- 03 Sep 2013 Planned end date changed from 1 Sep 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.